| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 151, Issue 11 6283-6290, Copyright © 1993 by American Association of Immunologists
ARTICLES |
E Lamouse-Smith, VK Clements and S Ostrand-Rosenberg
Department of Biological Sciences, University of Maryland, Baltimore 21228.
C57BL/6 mice with a disrupted beta 2M gene (beta 2M-/- mice) express very low levels of MHC class I molecules and are deficient for CD8+ T lymphocytes. Because CD8+ T cells are thought to be a principle effector cell in tumor rejection, we have assessed the ability of beta 2M-/- mice to respond to tumors. beta 2M-/- knockout mice were challenged with seven independent MHC allogeneic and syngeneic tumors. The beta 2M-/- mice responded very similarly to their CD8+ beta 2M+/- littermates in that they rejected high dose challenges of 4/5 allogeneic tumors and were susceptible to 3/3 syngeneic tumors. In vivo depletion of CD4+ or CD8+ cells from the beta 2M-/- mice resulted in susceptibility to allogeneic tumor. The apparent requirement for CD8+ cells for tumor immunity was corroborated by in vitro assays in which depletion of CD8+ but not CD4+ T cells eliminated tumor-specific CTL activity. mAb blocking studies in which target tumor cells were incubated with MHC class I-specific mAb demonstrated that the tumor- specific CD8+ activity was MHC class I restricted. beta 2M-/- mice therefore contain very small quantities of potent, CD8+ T cells that are capable of rejecting large challenges of allogeneic tumor cells.
This article has been cited by other articles:
|
|
 |
|
  D. S. Dace, P. W. Chen, H. Alizadeh, and J. Y. Niederkorn Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner J. Leukoc. Biol., February 1, 2007; 81(2): 421 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Dolan, K. D. Gibbs Jr, and S. Ostrand-Rosenberg Dendritic Cells Cross-Dressed with Peptide MHC Class I Complexes Prime CD8+ T Cells J. Immunol., November 1, 2006; 177(9): 6018 - 6024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bhattacharya, D. J. Rossi, D. Bryder, and I. L. Weissman Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning J. Exp. Med., January 23, 2006; 203(1): 73 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease J. Immunol., January 15, 2005; 174(2): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. Koido, J. Xia, M. Ohana, C. Liu, G. M. Cote, D. B. Sawyer, S. Calderwood, and J. Gong Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion J. Immunol., June 15, 2004; 172(12): 7848 - 7858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ribas, J. A. Wargo, B. Comin-Anduix, S. Sanetti, L. Y. Schumacher, C. McLean, V. B. Dissette, J. A. Glaspy, W. H. McBride, L. H. Butterfield, et al. Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells J. Immunol., April 15, 2004; 172(8): 4762 - 4769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease Cancer Res., March 15, 2004; 64(6): 2205 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Schell, L. M. Mylin, S. S. Tevethia, and S. Joyce The assembly of functional {beta}2-microglobulin-free MHC class I molecules that interact with peptides and CD8+ T lymphocytes Int. Immunol., July 1, 2002; 14(7): 775 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Surquin, A. Le Moine, V. Flamand, N. Nagy, K. Rombaut, F.-X. Demoor, P. Stordeur, I. Salmon, J.-C. Guery, M. Goldman, et al. Skin Graft Rejection Elicited by {beta}2-Microglobulin as a Minor Transplantation Antigen Involves Multiple Effector Pathways: Role of Fas-Fas Ligand Interactions and Th2-Dependent Graft Eosinophil Infiltrates J. Immunol., July 1, 2002; 169(1): 500 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hammond-McKibben, P. Lake, J. Zhang, N. Tart-Risher, R. Hugo, and M. Weetall A High-Capacity Quantitative Mouse Model of Drug-Mediated Immunosuppression Based on Rejection of an Allogeneic Subcutaneous Tumor J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1144 - 1151. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ostrand-Rosenberg, M. J. Grusby, and V. K. Clements Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma J. Immunol., December 1, 2000; 165(11): 6015 - 6019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nesic, F. R. Santori, and S. Vukmanovic {alpha}{beta}TCR+ Cells Are a Minimal Fraction of Peripheral CD8+ Pool in MHC Class I-Deficient Mice J. Immunol., August 15, 2000; 165(4): 1896 - 1901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kobayashi, K. Yoshida, J. M. Ward, J. J. Letterio, G. Longenecker, L. Yaswen, B. Mittleman, E. Mozes, A. B. Roberts, S. Karlsson, et al. {beta}2-Microglobulin-Deficient Background Ameliorates Lethal Phenotype of the TGF-{beta}1 Null Mouse J. Immunol., October 1, 1999; 163(7): 4013 - 4019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Vugmeyster, R. Glas, B. Perarnau, F. A. Lemonnier, H. Eisen, and H. Ploegh Major histocompatibility complex (MHC) class I KbDb -/- deficient mice possess functional CD8+ T cells and natural killer cells PNAS, October 13, 1998; 95(21): 12492 - 12497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zelenika, E. Adams, A. Mellor, E. Simpson, P. Chandler, B. Stockinger, H. Waldmann, and S. P. Cobbold Rejection of H-Y Disparate Skin Grafts by Monospecific CD4+ Th1 and Th2 Cells: No Requirement for CD8+ T Cells or B Cells J. Immunol., August 15, 1998; 161(4): 1868 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Freland, B. J. Chambers, M. Andersson, L. Van Kaer, and H.-G. Ljunggren Rejection of Allogeneic and Syngeneic But Not MHC Class I-Deficient Tumor Grafts by MHC Class I-Deficient Mice J. Immunol., January 15, 1998; 160(2): 572 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H de la Salle, D Hanau, D Fricker, A Urlacher, A Kelly, J Salamero, S. Powis, L Donato, H Bausinger, M Laforet, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency Science, July 8, 1994; 265(5169): 237 - 241. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
